Rejuvenating the portfolio
|
|
- Albert Ellis
- 5 years ago
- Views:
Transcription
1 Rejuvenating the portfolio Severin Schwan CEO The Octavian Seminar, Zuerich 2019
2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 2
3 Performance update Rejuvenating the portfolio Productivity Outlook 3
4 Q3 2018: Sales growth for the seventh consecutive year 10% 8% 6% 6% 6% 6% 8% 7% 5% 6% 7% 6% 6% 6% 6% 7% 7% 6% 4% 4% 4% 4% 5% 5% 4% 4% 4% 5% 2% 2% 3% 3% 0% Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 All growth rates at Constant Exchange Rates (CER) 4
5 HY 2018: Strong Core results, significant operating free cash flow Operating profit EPS Operating free cash flow % of sales 39.4% 38.5% 39.7% 21.9% 28.8% 28.6% CHFbn % at CER 11.2 CHF % 1 at CER CHFbn % at CER HY 2016 HY 2017 HY 2018 HY 2016 HY 2017 HY 2018 HY 2016 HY 2017 HY 2018 CER=Constant Exchange Rates 1 +8% at CER excl. US tax reform 5
6 CHF New product growth expected to show strong momentum Considerable optionality Sensitivity analysis: Assuming conservative planning assumptions of 60-70% erosion from biosimilars consensus sales growth* (CHF) Avastin 6.7 bn Mabthera 7.4 bn to fill: ~10 bn 1 4 bn Ocrevus Hemlibra Gazyva Alecensa In-market & mature 2 Pipeline value bn 2.3 bn 2.1 bn 1.0 bn 1.1 bn (0.6 bn) 0.4 bn Herceptin 7.0 bn 2017 Sales Perjeta Kadcyla Herceptin H+P SC 2022 Sales Total ~11 bn Up-side potential to consensus above are: Venclexta, SMA (risdiplam), Huntington (HTT- ASO), Autism (balovaptan), Alzheimer (gantenerumab & crenezumab), Ophthalmology (Port Delivery System), Infectious disease (baloxavir marboxil), Oncology (polatuzumab, idasanutlin, ipatasertib, mosunetuzumab) * Source: Roche post-hy2018 consensus; 1 Gap value including the total HER2 franchise change from 2017 to 2022, assuming Lucentis will be replaced by faricimab; 2 Esbriet, Tarceva, Xolair, Pulmozyme, Rocephin, CellCept, Mircera, NeoRecormon/Epogin, Activase/TNKase, Xeloda, Valcyte/Cymevene, Actemra, Tamiflu, Madopar, Pegasys; 3 etrolizumab 6
7 Near term pipeline carries significant revenue potential Submission Molecule Indication Market opportunity Submission Molecule Indication Market opportunity Hemlibra Hemophilia A, non-inhibitors 2018 Xofluza Influenza A & B polatuzumab vedotin Venclexta R/R DLBCL 1L AML 2019 satralizumab risdiplam Neuromyelitis optica SMA L NSq NSCLC 2020 anti-myostatin DMD 1L ES SCLC crenezumab Alzheimer s disease 1L TNBC HTT-ASO Huntington s disease + Avastin entrectinib RCC NSCLC ROS1+, NTRK balovaptan PDS Autism wamd idasanutlin AML faricimab DME Cotellic+/-Zelboraf BRAFm Mel, BRAFwt Mel neoadj TNBC etrolizumab UC/CD Venclexta + Gazyva 1L CLL + Avastin ipatasertib 1L HCC 1L CRPC, 1L TNBC, HER2-/HR+ BC Oncology / Hematology Ophthalmology Small: up to CHF 0.5 bn Avastin 1L muc CRPC 1L OC Neuroscience Immunology Infectious disease medium= CHF 0.5 to CHF 1bn large > CHF1bn 2021 polatuzumab vedotin 1L DLBCL 7
8 Performance update Rejuvenating the portfolio Productivity Outlook 8
9 Breakthrough innovation remains key Highest number in industry reflects quality of our research Phase duration (years) No = 7.5 Fast track = 5.8 Accelerated review = 3.8 Breakthrough therapy = 3.6 BTD=Breakthrough Therapy Designation; Data source: Evaluate Pharma, Decision Resources, Prismaccess 9
10 Replace and extend the business Through continuously improving standard of care Replace existing businesses Entering new franchises Why did we get more optimistic over the past years? MabThera/Rituxan Herceptin Avastin Lucentis Tamiflu Gazyva, Venclexta, polatuzumab vedotin, Subcutaneous Perjeta, Kadcyla, Subcutaneous, entrectinib, ipatasertib Faricimab, Port Delivery System Xofluza MS: Ocrevus Hemophilia A: Hemlibra CNS: SMA, Autism, Huntington s, Alzheimer s (+) New molecular entities (NMEs) with fast approval and up-take for Ocrevus, Alecensa, Perjeta, Venclexta, Hemlibra (+) Pipeline development with highest number of NMEs, in particular in CNS, Ophthalmology, Infectious Diseases VA2=aVEGF/ANG2 biab; MS=multiple sclerosis; SMA=spinal muscular atrophy; RMS=relapsing MS; PPMS=primary progressive MS; inhl=indolent Non-Hodgkin`s lymphoma; NSCLC=non-small cell lung cancer; ES-SCLC=extensive stage small cell lung cancer; RCC=renal cell carcinoma; TNBC=triple negative breast cancer; ebc=early breast cancer; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; DME=diabetic macular edema; wamd=wet age-related macular degeneration 10
11 Hematology: Building upon our leadership and experience Establishing new standards of care and expansion into new diseases Continuing to redefine the standard of care in B-cell malignancies Expanding into new hematologic diseases with transformative therapies 14% polatuzumab mosunetuzumab CD20/CD3 TCB CD20/CD3 TCB Non-malignant heme SKY59 idasanutlin anhl (DLBCL) anhl 14% (DLBCL) 14% Incidence rates 1 Incidence rates 1 Datamonitor: incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); CLL=Chronic lymphoid leukemia; DLBCL=Diffuse large B-cell lymphoma; inhl=indolent Non-Hodgkin's lymphoma; AML=Acute myeloid leukemia; MM=Multiple myeloma; MDS=Myelodysplastic syndrome; ALL=Acute lymphoblastic leukemia; Venclexta in collaboration with AbbVie 11
12 Breast cancer: Expanding into areas with high unmet need Continue defining the SoC in HER2+ BC pivotal trials Kadcyla in ebc KATHERINE disease free survival New opportunity 15% TNBC ipatasertib IPATunity130 (Ph III 1L Dx+) IMpassion130 (Ph III 1L), filed Roche marketed 20% Her2+ IMpassion131 (Ph III 1L) IMpassion132 (Ph III 1L) IMpassion031 (Ph III NeoAdj) IMpassion030 (Ph III Adj) KATHERINE (Ph III non-pcr Adj) New opportunity 65% Her2- HR+ IMpassion050 (Ph III NeoAdj) ipatasertib IPATunity130 (Ph III 1st chemo Dx+) Incidence rates (490,000 pts 1 ) 1 Source: Datamonitor and internal estimates, US & EU5; SoC=standard of care; BC=breast cancer; TNBC=triple negative breast cancer 12
13 Replace and extend the business Through continuously improving standard of care Replace existing businesses Entering new franchises Why did we get more optimistic over the past years? MabThera/Rituxan Herceptin Avastin Gazyva, Venclexta, polatuzumab vedotin, Subcutaneous Perjeta, Kadcyla, Subcutaneous, entrectinib, ipatasertib MS: Ocrevus Hemophilia A: Hemlibra (+) New molecular entities (NMEs) with fast approval and up-take for Ocrevus, Alecensa, Perjeta, Venclexta, Hemlibra (+) Pipeline development with highest number of NMEs, in particular in CNS, Ophthalmology, Infectious Diseases Lucentis Tamiflu Faricimab Port Delivery System Xofluza CNS: SMA, Autism, Huntington s, Alzheimer s VA2=aVEGF/ANG2 biab; MS=multiple sclerosis; SMA=spinal muscular atrophy; RMS=relapsing MS; PPMS=primary progressive MS; inhl=indolent Non-Hodgkin`s lymphoma; NSCLC=non-small cell lung cancer; ES-SCLC=extensive stage small cell lung cancer; RCC=renal cell carcinoma; TNBC=triple negative breast cancer; ebc=early breast cancer; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; DME=diabetic macular edema; wamd=wet age-related macular degeneration 13
14 Multiple Sclerosis Goal to be market leader in MS Ocrevus uniquely differentiated in RMS and PPMS Total MS market USD ~23bn in Efficacy RMS Superior to SOC DMT PPMS First therapy to show efficacy in setting 12% US: Total Patient Market Share as of Q Safety 70,000+ patients; 4-year safety data presented; no PML cases related to drug #1 US: New MS prescription Convenience IV twice yearly as of Mar 2018 Access Priced below or similar to high efficacy therapies, broad payer coverage in US, reimbursement ongoing in EU 32% US: New/switch Patient Share 1 as of Q SOC=Standard of Care; RMS=Relapsing Multiple Sclerosis; PPMS=Primary Progressive Multiple Sclerosis; 1. US IMS and Symphony claims data Q
15 Emerging opportunities in CNS Adressing high medical need Risdiplam in SMA Phase II/III (FIREFISH) Type 1 SMA Median change from baseline in CHOP-INTEND HTT-ASO in Huntington Pivotal trial initiated Balovaptan in autism (ASD) Pivotal trial initiated in adults* 20/21 babies (95%) were alive at 10.5m With 8 m treatment: 3 unassisted sitting babies Broad clinical program including Type 1 to 3 Highest doses: mean reductions of mhtt protein of 40% to 60% Safe and well tolerated Dose dependent treatment effect on VinelandTM-II score Ph II study in children ongoing * Primary endpoint (SRS-2) in Phase 1 not met 15
16 Transforming Healthcare through new era of data and analytics Deeper scientific insights (bench to bedside) Enhanced matching of patients with therapies Better, earlier go/no-go decisions Faster, more efficient trials Smarter, more efficient R&D Improved access & personalized care Improving access and value-based healthcare Accelerating optimization of care 16
17 Performance update Rejuvenating the portfolio Productivity Outlook 17
18 Transforming our operating model Building an effective organization for the future R&D Manufacturing Commercial +11% US Example: Filing of IMpassion 130 in 14 weeks (down from 26w) Volume HY 2018 vs. HY % Core COGS and Period Costs Europe LATAM APAC EEMEA US International Fit-for-purpose teams enabling fast, but rigorous decision making Faster filing initiatives (e.g. regulatory acceleration, dossier optimizing) PHC and data strategy driving insights and R&D efficiencies Lean management production program Favorable product mix Management of inventory Simplified structures, processes & culture to drive effectiveness Productivity initiatives Resource shift to support key launches EM=Emerging Market; PHC=Personalized Healthcare; COGS=cost of goods sold 18
19 Performance update Rejuvenating the portfolio Productivity Outlook 19
20 line extensions NMEs Q3 2018: Record number of NMEs at pivotal stage entrectinib polatuzumab vedotin polatuzumab vedotin ipatasertib ipatasertib Hemlibra Hemlibra idasanutlin Hemlibra idasanutlin Perjeta+Herceptin FDC SC idasanutlin Hemlibra taselisib faricimab taselisib Venclexta Alecensa lampalizumab satralizumab gantenerumab idasanutlin taselisib Alecensa lampalizumab crenezumab satralizumab faricimab risdiplam balovaptan anti-myostatin adnectin crenezumab satralizumab gantenerumab PDS with ranibizumab HTT-ASO risdiplam balovaptan anti-myostatin adnectin crenezumab satralizumab Oncology Ophthalmology Neuroscience Immunology Infectious Disease Ocrevus gantenerumab Ocrevus gantenerumab lebrikizumab Ocrevus baloxavir marboxil baloxavir marboxil etrolizumab etrolizumab etrolizumab etrolizumab FY 2015 FY 2016 FY 2017 Q NME=new molecular entities; baloxavir marboxil (Cap Endonuclease inhibitor); risdiplam (SMN2 splicer); FDC=Fixed dose combination; SC=Subcutaneous; PDS=Port delivery system For details on the indications and line extensions please consult the pipeline appendix 20
21 2018 outlook Group sales growth 1 Mid single digit Core EPS growth 1 Broadly in line with sales, excl. US tax reform benefit Mid teens incl. US tax reform Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 21
22 Doing now what patients need next
23 Staying Power: We have a leading oncology portfolio across multiple approaches and disease areas RG6123 FAP-IL2v Marketed In Development CIT molecule BET inh Selicrelumab RG6148 Tiragolumab Tiragolumab RG6123 Cotellic PCV FAP 4-1BBL RG6160 aher2/cd3 TDB Belvarafenib CD20/CD3 TCB Ipatasertib RG7769 RG6109 Venclexta FAP-IL2v RG70144 mosunetuzumab SERD (GDC-9545) PCV Alecensa Idasanutlin BET inh Polatuzumab vedotin Hemlibra Cotellic mpi3k alpha (0077) Xeloda Perjeta Tiragolumab Entrectinib Selicrelumab CEA-TCB Belvarafenib RG6123 CEA-TCB Selicrelumab Tiragolumab Tiragolumab FAP-IL2v IC Selicrelumab BET inh PD1-TIM3 PCV Tiragolumab Pan-Raf Selicrelumab atgfb Tiragolumab FAP-IL2v Selicrelumab Venclexta Kadcyla Alecensa Ipatasertib Tiragolumab Erivedge Idasanutlin GAZYVA Herceptin Tarceva Herceptin Avastin Zelboraf MabThera Avastin Avastin Avastin Avastin Cotellic Avastin Hematology Breast Lung GI 1 GU 2 Ovarian 3 Skin Other 4 1. Includes colorectal, gastric, liver and pancreatic; 2. Includes bladder, kidney and prostate; 3. Includes cervical and endometrial cancers with ongoing registrational studies with Avastin and ; 4. Includes, but not limited to, brain, cervical, head & neck, sarcoma and PVNS or indication not yet decided 23
24 Bringing transformative therapies to non-malignant hematology Hemophilia patient overview 1 Hemlibra transforming care for patients with and without inhibitors 20-25% 10% 5% 45% Hemophilia (inhibitor) treatment evolution bypassing agents 2017 Inhibitors 15% Non-inhibitors with bleeds Paediatric Non-inhibitors without bleeds Mild Hemophilia (non-inhibitor) R/R AML treatment evolution Factor VIII/ Modified FVIII 2018 Total hemophila A market growing to USD 13bn by Data from internal estimates 2. Evaluate Pharma 24
Rejuvenating the portfolio
Rejuvenating the portfolio Alan Hippe CFO UBS European Conference, London 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationRejuvenating the portfolio
Rejuvenating the portfolio Karl Mahler Head of Investor Relations Berenberg European Conference, London, December 2018 This presentation contains certain forward-looking statements. These forward-looking
More informationRejuvenating the portfolio
Rejuvenating the portfolio Alan Hippe, CFO J.P. Morgan, 37 th Annual Healthcare Conference, San Francisco 2019 This presentation contains certain forward-looking statements. These forward-looking statements
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationRejuvenating the portfolio
Rejuvenating the portfolio Severin Schwan CEO Bernstein Strategic Conference, New York, May 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationRejuvenating the portfolio
Rejuvenating the portfolio Alan Hippe CFO dbaccess Berlin Conference, June 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationInnovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015
Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words
More informationFocus and value creation
Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking
More informationInnovation and value creation
Innovation and value creation Severin Schwan, CEO Roche Bank am Bellevue Zuerich, January 2017 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Daniel O Day CEO Pharmaceuticals UBS Global Healthcare Conference, New York, May 2018 This presentation contains certain forward-looking statements. These forward-looking
More informationScience, patient benefits and productivity
Science, patient benefits and productivity Alan Hippe, CFO J.P. Morgan, January 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by
More information2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and
Appendix: Tables 1. Sales January to March 2016 and 2015... 2 2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015... 3 3. Pharmaceuticals Division... 4 4. Top 20 Pharmaceuticals
More informationCommitted to innovation and growth
Committed to innovation and growth Stefan Frings - Medical Director Germany London November 2016 2 This presentation contains certain forward-looking statements. These forward-looking statements may be
More informationContinuing to drive innovation
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationInnovation and growth
Innovation and growth Alan Hippe, CFO Roche Group Jefferies Healthcare Conference, June 2014 Performance update Industry in context Building pillars of growth / ASCO 2014 Summary 2 Q1 2014: Strong sales
More informationInnovation and value creation
Innovation and value creation Daniel O Day, CEO Roche Pharmaceuticals J.P. Morgan Healthcare Conference San Francisco, January, 2017 1 This presentation contains certain forward-looking statements. These
More informationTurning innovation into patients benefit
Turning innovation into patients benefit Karl Mahler, Head Investor Relations Zuerich, August 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be
More informationInnovation and growth
Innovation and growth Bill Anderson Head of Global Product Strategy and Chief Marketing Officer Jefferies Healthcare Conference London, November 2014 This presentation contains certain forward-looking
More informationRoche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011
Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationRoche delivers good sales growth in the first nine months of 2016
Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division
More informationRoche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationJanuary March CHF m CHF m In CHF
1. Sales January to March 2011 and 2010 2011 2010 % change January March CHF m CHF m In CHF In local currencies Pharmaceuticals Division 8,712 9,727-10 -2 United States 3,322 3,647-9 +2 Western Europe
More informationRoche Virtual Late Stage Pipeline Event Basel, 13 September 2018, 14:00-16:00 CEST
Roche Virtual Late Stage Pipeline Event 2018 Basel, 13 September 2018, 14:00-16:00 CEST This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More information2018 American Society of Hematology's 60th Annual Meeting Roche Analyst Audio Webcast. 4 December, 2018
2018 American Society of Hematology's 60th Annual Meeting Roche Analyst Audio Webcast 4 December, 2018 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationTranslating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals
Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain
More informationLondon, 31 January 2019
Roche 2018 results London, 31 January 2019 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationSales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12,
Investor Update Basel, 26 April 2018 Roche reports a strong start in 2018 Group sales increase 6% 1 at constant exchange rates and 5% in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly
More informationRoche. YTD September 2017 sales. Basel, 19 October 2017
Roche YTD September 2017 sales Basel, 19 October 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationRoche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010
Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationUBS European Conference 2013
UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth
More informationDevelopment pipeline (as of January 31, 2019)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2018 (IFRS) 14 Development pipeline (as of January 31, 2019) Oncology GA101 / RG7159 Follicular lymphoma
More informationSales CHF millions As % of sales % change. In CHF Group sales 12,942 12,
Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationRoche delivers continued growth in the first half of 2016
Investor Update Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales
More informationDevelopment pipeline (as of July 26, 2018)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 2nd quarter of FY2018 (IFRS) 12 Development pipeline (as of July 26, 2018) Oncology Additional
More informationRoche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change
Investor Update Basel, 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division
More informationRoche. Q results. Basel, 26 April 2018
Roche Q1 2018 results Basel, 26 April 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationRoche. Pascal Soriot COO Roche Pharmaceuticals
1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationCommitted to innovation and growth
Committed to innovation and growth Karl Mahler Head of Investor Relations Bill Anderson Head of Global Product Strategy June 2013 This presentation contains certain forward-looking statements. These forward-looking
More informationDevelopment pipeline (as of February 1, 2018)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2017 (IFRS) 12 Development pipeline (as of February 1, 2018) Development code (Compound number) Oncology
More informationRoche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance
Media Release Basel, 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER 1 to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months
More informationRoche. YTD September 2017 sales. Basel, 19 October 2017
Roche YTD September 2017 sales Basel, 19 October 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationDevelopment pipeline (as of February 1, 2017)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2016 (IFRS) 13 Development pipeline (as of February 1, 2017) Oncology Additional indication name
More informationSUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E
February 6, 2015 Roche Holding AG Current Recommendation Prior Recommendation Neutral Date of Last Change 02/06/2015 Current Price (02/05/15) $33.81 Target Price $31.00 UNDERPERFORM SUMMARY (RHHBY-OTC)
More informationCommitted to innovation and growth
Committed to innovation and growth Karl Mahler Head of Investor Relations Stefan Frings Oncology/Immunology Therapeutic Area Head Roche Partnering Roche Group June 2013 This presentation contains certain
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationDiagnostics Division. Daniel O Day COO Roche Diagnostics
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationRoche: Committed to Innovation
Roche: Committed to Innovation William M. Burns CEO Roche Pharmaceuticals UBS Swiss Equity Conference, Zurich, 26. November 2009 This presentation contains certain forward-looking statements. These forward-looking
More informationCore earnings per share up 7% at constant exchange rates, 0% in Swiss francs
Investor Update Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%
More informationCore EPS growth ahead of sales, up 10% to Swiss francs
Investor Update Basel, 30 January 2014 Roche delivers strong 2013 results Group sales rise 6% 1 to 46.8 billion Swiss francs Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin,
More informationMedia Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in
More informationCommitted to innovation and growth
Committed to innovation and growth Roland Diggelmann, CEO Roche Diagnostics Paris, November 30, 2016 Q3 2016 Group results Diagnostics Business model & strategy Q3 2016 overview Investing in innovation
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationInvestor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012
Investor Update Basel, February 0 Roche in : Strong results and positive outlook Group sales rise % (-0% in Swiss francs; +6% in US dollars), excluding Tamiflu. Significant foreign exchange impact of percentage
More informationPipeline summary. Marketed products additional indications. Global Development late-stage trials. pred (Roche Pharma Research & Early Development)
Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group
More informationCore earnings per share up 7% at constant exchange rates, 0% in Swiss francs
Media Release Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%
More informationNine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587
Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss
More informationPipeline summary. Marketed products additional indications. Global Development late-stage trials. pred (Roche Pharma Research & Early Development)
Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group
More informationInvestor Update. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013
Investor Update Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net income
More informationRoche. Q sales. Basel, 27 April 2017
Roche Q1 2017 sales Basel, 27 April 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationRoche reports strong performance in the first half of 2017
Investor Update Basel, 27 July 2017 Roche reports strong performance in the first half of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up
More informationRoche. Q results. Basel, 26 April 2018
Roche Q1 2018 results Basel, 26 April 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationRoche delivers strong performance in the first half of 2015
Investor Update Basel, 23 July Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationRoche. YTD September 2016 sales. Basel, 20 October 2016
Roche YTD September 2016 sales Basel, 20 October 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationRoche. YTD September 2014 sales. Basel, 16 October 2014
Roche YTD September 2014 sales Basel, 16 October 2014 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationESMO IO Congress 2017, Geneva. Roche Analyst Call. Thursday, 7 December 2017
ESMO IO Congress 2017, Geneva Roche Analyst Call Thursday, 7 December 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAlan Hippe CFO Roche Group. New York, June 2015
Alan Hippe CFO Roche Group New York, June 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationRoche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal
More informationRoche on track for full-year targets good sales growth in first quarter
Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationPipeline summary. Marketed products additional indications. Global Development late-stage trials. pred (Roche Pharma Research & Early Development)
Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationMedia Release. Roche committed to innovation and growth. Basel and London, 5 September 2012
Media Release Basel and London, 5 September 2012 Roche committed to innovation and growth Personalised healthcare leadership and world-class pipeline presented at investor conference Industry-leading pipeline
More informationDr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader Avastin
Roche Positioning AVASTIN-based therapy as essential to treat cancer Dr. Karl Mahler, Head of Investor Relations Dr. Stefan Frings, Life Cycle Leader This presentation contains certain forward-looking
More informationRoche: Building on strength
Roche: Building on strength Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO 1 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationMedia Release. Basel, 10 December 2017
Media Release Basel, 10 December 2017 Phase II data showed Roche s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone
More informationAiming to Achieve the Mid-term Business Plan IBI 18 - FY2018 Half Year Results -
Aiming to Achieve the Mid-term Business Plan IBI 18 - FY2018 Half Year Results - CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Tatsuro Kosaka July 26/27, 2018 Forward-Looking Statements - FY2018 Half
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationRoche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting
Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational
More informationRoche. YTD September 2016 sales. Basel, 20 October 2016
Roche YTD September 2016 sales Basel, 20 October 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,
More informationRoche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials
Media Release Basel, 14 April 2011 Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Group Group sales stable in local currencies (-9%
More informationRoche. Q sales. April 11, 2013
1 Roche Q1 2013 sales April 11, 2013 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationMedia Release. CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval of Roche s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More information